October 24, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. (hereafter, ''Chugai'') [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] announced today that a supply plan of the anti-influenza drug "Tamiflu® Capsule 75" and "Tamiflu® Dry Syrup 3%" (generic name: oseltamivir phosphate) (hereafter, Tamiflu®) imported from F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland. CEO: Severin Schwan] for the 2013-2014 season (hereafter, this season) for Japan has been prepared.
Supply plan for this season (as of October 24, 2013)
Tamiflu® Capsule 755.0 million treatment courses
Tamiflu® Dry Syrup 3%3.0 million treatment courses
Total of 8.0 million treatment courses
Chugai will consider supplying further if the size of the epidemic of influenza expands.
Chugai is determined to be ready for the supply of Tamiflu® in preparation for the epidemic of influenza.
Tamiflu® is trademark of F. Hoffmann-La Roche Ltd., Basel, Switzerland.
To read more Press Release articles, click here.